New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial

NCT ID NCT05631262

Ongoing Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the safety and effectiveness of SKB264, a new drug, in 321 adults with advanced solid tumors, specifically non-small cell lung cancer and nasopharyngeal carcinoma. Participants receive SKB264 alone until the drug stops working or side effects become too severe. The study measures how many patients see their tumors shrink and tracks any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a drug given intravenously)
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors like lung or nasopharyngeal cancer.
What could go wrong: This is an early-phase trial with no guarantee of benefit. Side effects may be serious, and the drug may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SELECTED SUBJECTS WITH ADVANCED SOLID TUMORS

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.